LEADER 01491cam a22003014a 4500 001 991001101789707536 008 100319s2000 enka b 001 0 eng d 020 $a9780471970699 035 $ab13960726-39ule_inst 040 $aDip.to Ingegneria dell'Innovazione$beng 082 0 $a621.381331$221 100 1 $aConciauro, Giuseppe$09840 245 10$aAdvanced modal analysis :$bCAD techniques for waveguide components and filters /$cGiuseppe Conciauro, Marco Guglielmi, Roberto Sorrentino 260 $aChichester ;$aNew York :$bJohn Wiley & Sons,$cc2000 300 $axii, 341 p. :$bill. ;$c25 cm 504 $aIncludes bibliographical references and index 650 4$aMicrowave transmission lines$xMathematical models$xData processing 650 4$aModal analysis$xData processing 650 4$aMicrowave filters$xMathematical models$xData processing 700 1 $aGuglielmi, Marco$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0719294 700 1 $aSorrentino, Roberto$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0471518 856 4 $zTable of Contents$uhttp://www.loc.gov/catdir/toc/onix01/99026512.html 907 $a.b13960726$b07-04-22$c14-03-11 912 $a991001101789707536 945 $aLE026 621.381 D CON 01.01 2000$g1$i2026000057811$lle026$nProf. Tarricone / Biblioteca$op$pE90.32$q-$rn$s- $t1$u17$v0$w17$x0$y.i15239731$z14-03-11 996 $aAdvanced modal analysis$91396342 997 $aUNISALENTO 998 $ale026$b19-03-10$cm$da $e-$feng$genk$h0$i0 LEADER 03940nam 2200697 a 450 001 9910779535103321 005 20230217231253.0 010 $a0-674-06104-7 024 7 $a10.4159/harvard.9780674061040 035 $a(CKB)2550000001039403 035 $a(EBL)3301254 035 $a(SSID)ssj0000860459 035 $a(PQKBManifestationID)11441001 035 $a(PQKBTitleCode)TC0000860459 035 $a(PQKBWorkID)10897355 035 $a(PQKB)10205058 035 $a(MiAaPQ)EBC3301254 035 $a(DE-B1597)178235 035 $a(OCoLC)1013963976 035 $a(OCoLC)1037979673 035 $a(OCoLC)1041992873 035 $a(OCoLC)1046613091 035 $a(OCoLC)1047012253 035 $a(OCoLC)1049658335 035 $a(OCoLC)1054866187 035 $a(OCoLC)840444606 035 $a(DE-B1597)9780674061040 035 $a(Au-PeEL)EBL3301254 035 $a(CaPaEBR)ebr10678685 035 $a(OCoLC)835787969 035 $a(EXLCZ)992550000001039403 100 $a20101130d2011 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 12$aA long goodbye$b[electronic resource] $ethe Soviet withdrawal from Afghanistan /$fArtemy M. Kalinovsky 210 $aCambridge, Mass. $cHarvard University Press$d2011 215 $a1 online resource (304 pages) $cillustrations, maps 300 $aDescription based upon print version of record. 311 0 $a0-674-05866-6 320 $aIncludes bibliographical references and index. 327 $aThe reluctant intervention -- The turn toward diplomacy -- Gorbachev confronts Afghanistan -- The national reconciliation campaign -- Engaging with the Americans -- The Army withdraws and the Politburo debates -- Soviet policy adrift. 330 $aThe conflict in Afghanistan looms large in the collective consciousness of Americans. What has the United States achieved, and how will it withdraw without sacrificing those gains? The Soviet Union confronted these same questions in the 1980's, and Artemy Kalinovsky's history of the USSR's nine-year struggle to extricate itself from Afghanistan and bring its troops home provides a sobering perspective on exit options in the region. What makes Kalinovsky's intense account both timely and important is its focus not on motives for initiating the conflict but on the factors that prevented the Soviet leadership from ending a demoralizing war. Why did the USSR linger for so long, given that key elites recognized the blunder of the mission shortly after the initial deployment? Newly available archival material, supplemented by interviews with major actors, allows Kalinovsky to reconstruct the fierce debates among Soviet diplomats, KGB officials, the Red Army, and top Politburo figures. The fear that withdrawal would diminish the USSR's status as leader of the Third World is palpable in these disagreements, as are the competing interests of Afghan factions and the Soviet Union's superpower rival in the West. This book challenges many widely held views about the actual costs of the conflict to the Soviet leadership, and its findings illuminate the Cold War context of a military engagement that went very wrong, for much too long. 606 $aDisengagement (Military science)$vCase studies 607 $aSoviet Union$xForeign relations$zAfghanistan 607 $aAfghanistan$xForeign relations$zSoviet Union 607 $aAfghanistan$xHistory$ySoviet occupation, 1979-1989 607 $aSoviet Union$xForeign relations$y1975-1985 607 $aSoviet Union$xForeign relations$y1985-1991 615 0$aDisengagement (Military science) 676 $a958.104/5 700 $aKalinovsky$b Artemy M$01461945 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910779535103321 996 $aA long goodbye$93670785 997 $aUNINA LEADER 05646nam 22007215 450 001 9910300208003321 005 20250709113221.0 010 $a1-4939-1393-X 024 7 $a10.1007/978-1-4939-1393-0 035 $a(CKB)3710000000291268 035 $a(EBL)1968238 035 $a(OCoLC)896824700 035 $a(SSID)ssj0001386808 035 $a(PQKBManifestationID)11884114 035 $a(PQKBTitleCode)TC0001386808 035 $a(PQKBWorkID)11374491 035 $a(PQKB)10174111 035 $a(DE-He213)978-1-4939-1393-0 035 $a(MiAaPQ)EBC1968238 035 $a(PPN)183098021 035 $a(EXLCZ)993710000000291268 100 $a20141120d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aTargeted Therapy of Acute Myeloid Leukemia /$fedited by Michael Andreeff 205 $a1st ed. 2015. 210 1$aNew York, NY :$cSpringer New York :$cImprint: Springer,$d2015. 215 $a1 online resource (804 p.) 225 1 $aCurrent Cancer Research,$x2199-2592 300 $aDescription based upon print version of record. 311 08$a1-4939-1392-1 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aIntroduction/Perspective -- Genetics and Classification of Acute Myeloid Leukemia -- Proteomics of AML to guide Selection of Therapy -- Roles of Apoptosis Regulating Bcl-2-Family Genes in AML -- Bcl-2 family: Translational aspects -- IAP Family and Proteins as Therapeutic Targets for Acute Myeloid Leukemia -- TP53 Mutations in Acute Myeloid Leukemia -- Targeting p53 Tumor Suppressor for AML Therapy -- AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion Protein -- PIM Kinases in AML -- Development of Midostaurin as a Tyrosine Kinase Inhabitor -- FLT3 in AML -- FLT3-ITD. Clinical (Sorafenib/AC220) -- Nucleophosmin (NPM1) -- Raf/MEK Pathway -- The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase Pathway -- Clinical Use of Farnesyltransferase Inhititors -- The P13K-AKT-mTOR signaling Network in AML -- Targeting the P13 Kinase-mTOR Signaling Pathway in AML -- Aurora kinases -- The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia -- AML-Deacetylases -- Methylation in AML-Clinical Applications -- Topic: RARa/RXR  Part: Basic -- Arsenic Trioxide in Untreated APL -- Targeting PML-RAR? with Retinoids -- NR4A Orphan Receptors as Drug Targets -- Antibody-based Therapeutics Targeting CD33, CD45, and CD66 -- New Heterogeneity of the Leukemic Stem Cells -- Targeting Leukemia Stem Cells -- Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling -- CXC4/CXCL12 as a Therapeutic Target -- VLA-4: A Cell?s Consequential Encounter -- VLA-4 Function and Prognosis in Acute Myeloid Leukemia -- VLA4 in Acute Lymphoblastic Leukemia -- The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs -- Topic: miRs as Therapeutic Targets -- Clinical Implications of MicroRNAs in AML -- Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias -- Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells -- NK Cell Immunotherapy for AML -- Allogeneicand Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemia -- Indications for Hematopoietic Transplantation for AML -- Mesenchymal Stem/Stromal Cell Targeted Therapies for Solid Tumors and Hematological Malignancies. 330 $aThis book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where  leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia. . 410 0$aCurrent Cancer Research,$x2199-2592 606 $aCancer 606 $aPharmacology 606 $aCytology 606 $aMicrobiology 606 $aCancer Biology 606 $aPharmacology 606 $aCell Biology 606 $aMicrobiology 615 0$aCancer. 615 0$aPharmacology. 615 0$aCytology. 615 0$aMicrobiology. 615 14$aCancer Biology. 615 24$aPharmacology. 615 24$aCell Biology. 615 24$aMicrobiology. 676 $a571.6 676 $a579 676 $a610 676 $a614.5999 702 $aAndreeff$b Michael$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300208003321 996 $aTargeted Therapy of Acute Myeloid Leukemia$91821467 997 $aUNINA